QUIDELORTHO Aktie

>QUIDELORTHO Aktienkurs

14.2 EUR -1.4% (TradegateBSX)

Ask: 15 EUR / 1300 Stück

Bid: 14.9 EUR / 675 Stück

Tagesumsatz: 600 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

QUIDELORTHO Aktie über LYNX handeln

Intraday

1 Jahr

>QUIDELORTHO Performance

1 Woche: +10,5%

1 Monat: -23,5%

3 Monate: -40,3%

6 Monate: -45,0%

1 Jahr: -51,7%

laufendes Jahr: -43,2%

>QUIDELORTHO Aktie

Name:

QUIDELORTHO DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US2197981051 / A3DNGX

Symbol/ Ticker:

QL1A (Frankfurt) / QDEL (NASDAQ)

Kürzel:

FRA:QL1A, ETR:QL1A, QL1A:GR, NASDAQ:QDEL

Index:

Webseite:

https://www.quidelortho.c..

Profil:

QuidelOrtho Corporation is a leading manufacturer and provider of diagnostic testing solutions that serve the healthcare industry on a global scale. The company focuses on developing innovative diagnostic products designed to detect and diagnose a va..
>Volltext..

Marktkapitalisierung:

977.89 Mio. EUR

Unternehmenswert:

3245.13 Mio. EUR

Umsatz:

2367.46 Mio. EUR

EBITDA:

433.76 Mio. EUR

Nettogewinn:

-980.49 Mio. EUR

Gewinn je Aktie:

-14.43 EUR

Schulden:

2455.05 Mio. EUR

Liquide Mittel:

147.1 Mio. EUR

Operativer Cashflow:

91.14 Mio. EUR

Bargeldquote:

0.18

Umsatzwachstum:

-13.4%

Gewinnwachstum:

50.79%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

QUIDELORTHO

Letzte Datenerhebung:

05.04.26

>QUIDELORTHO Kennzahlen

Aktien/ Unternehmen:

Aktien: 68.08 Mio. St.

Frei handelbar: 98.96%

Leerverk. Aktien: 16.15%

Rückkaufquote: -0.54%

Mitarbeiter: 6500

Umsatz/Mitarb.: 0.36 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: 101.92%

Bewertung:

KGV: -

KGV lG: 7.64

KUV: 0.37

KBV: 0.59

PEG-Ratio: -

EV/EBITDA: 7.48

Rentabilität:

Bruttomarge: 39.85%

Gewinnmarge: -41.42%

Operative Marge: 2.15%

Managementeffizenz:

Gesamtkaprendite: -17.77%

Eigenkaprendite: -46.15%

>QUIDELORTHO Peer Group

Gesundheit

>QUIDELORTHO Chart & Kurs - NASDAQ

>QUIDELORTHO News

24.03.26 - 12:01	Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer (PR Newswire)
	SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will......

13.03.26 - 18:00	Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report? (Zacks)
	QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

09.03.26 - 14:36	Rice Hall James Buys QuidelOrtho Stock (Fool)
	QuidelOrtho develops diagnostic technologies for healthcare providers worldwide, spanning labs, clinics, and retail settings....

04.03.26 - 07:31	QuidelOrtho präsentiert Wachstumsstrategie auf Raymond James Konferenz (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.03.26 - 04:00	QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires (Fool)
	QuidelOrtho Corporation's stock has been falling for multiple years, but after a board member purchased shares, could the stock soon reverse?...

19.02.26 - 15:18	Faster Cardiac Answers with High‑Sensitivity Troponin (PR Newswire)
	SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host......

18.02.26 - 22:06	QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference (PR Newswire)
	SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor......

17.02.26 - 19:00	QDEL Expands Immunoassay Portfolio Via Lifotronic Supply Agreement (Zacks)
	QuidelOrtho inks Lifotronic supply deal, adding 70+ assays and new analyzer platforms to boost global immunoassay reach and recurring revenue potential....

16.02.26 - 07:06	QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio (PR Newswire)
	Agreement adds new analyzer platforms and expands assay menu across key international markets SAN DIEGO, Feb. 16, 2026 /PRNewswire/ -- QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389),......

14.02.26 - 03:01	Insiderhandel: Aufsichtsrat kauft Aktien von Quidel im Wert von 239586 USD (Insiderkauf)
	Strobeck, Matthew - Aufsichtsrat - Tag der Transaktion: 2026-02-13...

13.02.26 - 23:01	Insiderhandel: Chief Financial Officer kauft Aktien von Quidel im Wert von 79742 USD (Insiderkauf)
	Busky, Joseph M. - Vorstand - Tag der Transaktion: 2026-02-13...

13.02.26 - 19:01	Insiderhandel: President and CEO kauft Aktien von Quidel im Wert von 248661 USD (Insiderkauf)
	Blaser, Brian J. - Vorstand - Tag der Transaktion: 2026-02-13...

12.02.26 - 16:45	QuidelOrtho Q4 Earnings and Revenues Beat Estimates, Margins Down (Zacks)
	QDEL beats Q4 estimates as Labs and global growth lift sales, but shrinking margins and respiratory weakness weigh on profits....

12.02.26 - 04:09	QuidelOrtho outlines $2.7B–$2.9B 2026 revenue target as company advances R&D pipeline and margin expansion (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 01:00	QuidelOrtho (QDEL) Q4 2025 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 01:00	QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates (Zacks)
	QuidelOrtho (QDEL) delivered earnings and revenue surprises of +7.80% and +3.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.02.26 - 00:42	QuidelOrtho verfehlt Gewinnerwartung für Q4 2025 – Aktie gibt nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.02.26 - 22:06	QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results (PR Newswire)
	― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho......

04.02.26 - 17:30	Earnings Preview: QuidelOrtho (QDEL) Q4 Earnings Expected to Decline (Zacks)
	QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

03.02.26 - 13:15	QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards (PR Newswire)
	– First medical device company to receive excellence recognition in accordance with ISO 23592 – Gold Stevie® Award for Customer Service Success – Bronze Stevie® Award for AI & Tech Focused Digital Transformation Team of the Year SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- QuidelOrtho......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram